March 23rd, 2017
Consistent strong performance sees Helsinn Advanced Synthesis SA win six awards for the third consecutive year in Quality, Reliability, Capabilities, ...Read article
February 21st, 2017
Significant new investment totaling CHF15m,supported by Canton of Ticino, prompted by expanding demand for anticancer therapeutics Importanti nuovi in...Read article
February 15th, 2017
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announces that the Group has provided a grant to the European Society f...Read article
February 14th, 2017
Anti-emetic products covered under expanded agreements include ALOXI® and AKYNZEO®. Both are prophylactic agents for the treatment of chemotherapy ind...Read article
February 13th, 2017
Patient Assistance Program and Voucher Program will support both insured and uninsured patients in the United States get access to medicines that can ...Read article
Helsinn will be present in Madrid, Spain on 8-12 September 2017, at the ESMO 2017 congress.
You can meet us at booth #65.
The "2017 ASCO Annual Meeting -Making a Difference in Cancer Care" will take place in Chicago, Illinois, on June 2-6 2017
CPhI Japan is the largest japanese pharmaceutical exhibition